Infusion reaction to infliximab biosimilar after transitioning from infliximab
Open Access
- 1 February 2021
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 8, 77-79
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of ImmunogenicityAnnals of Laboratory Medicine, 2020
- Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and AggregatesFrontiers in Immunology, 2019
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trialThe Lancet, 2017
- Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohortExpert Opinion on Drug Safety, 2017
- Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical OverviewDrugs, 2017
- Infliximab-Related Infusion Reactions: Systematic ReviewJournal of Crohn's and Colitis, 2015
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trialJournal of the American Academy of Dermatology, 2010